AB Soft ii specs

16.Cleeland CS. Measurement and prevalence of pain in cancer. Semin Oncol Nurs 1(2): 87-92, 5/1985.

17.Cleeland CS. How to treat a "construct". J Pain Symptom Manage 1(3): 161-162, 1986.

18.Cleeland CS, Ladinsky JL, Serlin RC, Nugyen CT. Multidimensional measurement of cancer pain: comparisons of US and Vietnamese patients. J Pain Symptom Manage 3(1): 23-27, 1988.

19.Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, eds. Issues in Pain Measurement. New York: Raven Press; pp. 391-403, 1989 Advances in Pain Research and Therapy; Vol. 12.

20.Cleeland CS. Pain assessment. In: Lipton S, editor. Issues in

Pain Management. New York: Raven Press; pp. 287-291, 1990 Advances in Pain Research and Therapy; Vol. 12.

21.Cleeland CS. Assessment of pain in cancer: Measurement

issues. In: Foley KM, editor. Advances in Pain Research and

Therapy. New York: Raven Press; pp. 47-55, 1990 Vol. 16.

22.Cleeland CS. Pain Assessment in Cancer. In: Osoba D, editor.

Effect of Cancer on Quality of Life. Boca Raton: CRC Press; 1991.

23.Cleeland CS, Syrjala KL. How to assess cancer pain. In: Turk D,

Melzack R, editors. Pain Assessment. New York: Guilford Press; pp. 360-387, 1992.

24.Cleeland CS, Ryan KM. Pain assessment: global use of the

Brief Pain Inventory. Ann Acad Med Singapore 23(2): 129-138, 3/1994.

25.Cleeland CS, Bruera E. Managing Cancer Pain. In: Brain MC, Carbone PP, editors. Current Therapy in Hematology- Oncology. St. Louis: Mosby; pp. 571-578, 1995.

26.Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 67(2-3): 267-273, 10/1996.

27.Cleeland CS, Serlin RC, Nakamura Y, Mendoza TR. Effects of culture and language on ratings of cancer pain and patterns of functional interference. In: Jensen TS, Turner JA, Wiesenfeld- Hallin Z, editors. Progress in Pain Research and Management. Seattle: IASP Press; pp. 35-51, 1997 Proceedings of the 8th World Congress on Pain; Vol. 8.

28.Cleeland CS. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl 91(439): 43-47, 2002.

29.Cleeland CS, Anderson KO. Assessment of cancer-related symptoms: relevance for CAM research methodology. In: Expert Opinions on Methodology: Development of Cancer CAM Symptom Research, Publication No. 03-5427 [Final Report From the Expert Panel on Symptom Research, Nov 29- 30, 2001]. Bethesda, MD: National Cancer Institute; pp. 67-90, 9/2003.

30.Cook K, Johnson K, Amtmann D. (936): The impact on reliability of scoring the brief pain inventory interference scale with fewer than eleven categories. The Journal of Pain 7(4, Supplement 1): S83, 4/2006.

31.Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 50(9): 1913-1918, 11/1982.

32.Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17(2): 197-210, 10/1983.

33.Donovan KA, Taliaferro LA, Brock CW, Bazargan S. Sex Differences in the Adequacy of Pain Management among Patients Referred to a Multidisciplinary Cancer Pain Clinic. J Pain Symptom Manage, 4/2008.

34.Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey